Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,981.00
Bid: 1,985.00
Ask: 1,987.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.101%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,981.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS: Morgan Stanley Upgrades Barclays To Overweight

Tue, 03rd Feb 2015 09:38

LONDON (Alliance News) - The following UK shares received analyst recommendations Tuesday morning:
----------
FTSE 100
----------
UBS RAISES SKY PLC PRICE TARGET TO 1200 (1100) PENCE - 'BUY'
----------
BERENBERG CUTS ASHTEAD GROUP PRICE TARGET TO 1295 (1345) PENCE - 'BUY'
----------
CITIGROUP RAISES WOLSELEY PRICE TARGET TO 3900 (3800) PENCE - 'NEUTRAL'
----------
JPMORGAN CUTS SHELL A TO 'NEUTRAL' ('OVERWEIGHT') - PRICE TARGET 2100 (2500) PENCE
----------
PANMURE INITIATES MEGGITT WITH 'BUY' - TARGET 698 PENCE
----------
MORGAN STANLEY RAISES BARCLAYS TO 'OVERWEIGHT' ('EQUALWEIGHT') - PRICE TARGET 315 (270) PENCE
----------
FTSE 250
----------
BARCLAYS RAISES BRITVIC TO 'OVERWEIGHT' ('EQUALWEIGHT') - TARGET 800 (725) PENCE
----------
GOLDMAN CUTS NMC HEALTH TO 'NEUTRAL' ('BUY') - TARGET 575 (578) PENCE
----------
GOLDMAN RAISES AL NOOR HOSPITALS PRICE TARGET TO 1306 (1266) PENCE - 'BUY'
----------
GOLDMAN SACHS RAISES HIKMA PHARMACEUTICALS PRICE TARGET TO 2410 (2120) PENCE - 'NEUTRAL'
----------
NOMURA CUTS AMEC PRICE TARGET TO 1000 (1220) PENCE - 'BUY'
----------
NOMURA RAISES HUNTING TO 'NEUTRAL' ('REDUCE') - TARGET 390 (570) PENCE
----------
NOMURA CUTS JOHN WOOD PRICE TARGET TO 435 (520) PENCE - 'REDUCE'
----------
PANMURE INITIATES SENIOR PLC WITH 'BUY' - TARGET 417 PENCE
----------
NUMIS CUTS ZOOPLA PROPERTY PRICE TARGET TO 215 (235) PENCE - 'ADD'
----------
MAIN MARKET AND AIM
----------
UBS CUTS DARTY PRICE TARGET TO 90 (95) PENCE - 'BUY'
----------
BERENBERG CUTS ASOS PRICE TARGET TO 3500 (3785) PENCE - 'BUY'
----------
NOMURA CUTS LAMPRELL PRICE TARGET TO 125 (200) PENCE - 'BUY'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
6 Aug 2021 12:07

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

Read more
6 Aug 2021 09:03

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

Read more
6 Aug 2021 08:40

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

Read more
6 Aug 2021 07:42

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

Read more
6 Aug 2021 07:22

Hikma lifts FY generics guidance as first-half profits, revenue jump

(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance for its generics arm and reported a rise in first-half profit and revenue as it hailed a strong performance in both the generics and branded segments, and resilience in the injectables business.

Read more
30 Jul 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
14 Jul 2021 19:38

IN BRIEF: Arecor ends first half of 2021 with solid cash position

IN BRIEF: Arecor ends first half of 2021 with solid cash position

Read more
13 Jul 2021 10:00

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

Read more
1 Jul 2021 09:51

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

Read more
21 Jun 2021 14:51

UPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...

Read more
21 Jun 2021 14:31

U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's La...

Read more
8 Jun 2021 13:54

Tuesday broker round-up

(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.

Read more
6 May 2021 09:46

BROKER RATINGS: Exane BNP downgrades three property companies

BROKER RATINGS: Exane BNP downgrades three property companies

Read more
30 Apr 2021 17:01

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

Read more
30 Apr 2021 08:58

TOP NEWS: Hikma Pharma confident after promising start to year

TOP NEWS: Hikma Pharma confident after promising start to year

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.